U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282041) titled 'Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis' on Dec. 02.
Brief Summary: One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. We believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA).
In this open label randomised clinical trial, patients with recently symptoma...